Mark S. Rubin

709 total citations
14 papers, 492 citations indexed

About

Mark S. Rubin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark S. Rubin has authored 14 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark S. Rubin's work include Melanoma and MAPK Pathways (3 papers), Cancer therapeutics and mechanisms (2 papers) and Cancer Diagnosis and Treatment (2 papers). Mark S. Rubin is often cited by papers focused on Melanoma and MAPK Pathways (3 papers), Cancer therapeutics and mechanisms (2 papers) and Cancer Diagnosis and Treatment (2 papers). Mark S. Rubin collaborates with scholars based in United States, Australia and United Kingdom. Mark S. Rubin's co-authors include John D. Hainsworth, David R. Spigel, Raven Quinn, F. Anthony Greco, Ralph V. Boccia, Howard A. Burris, Dana S. Thompson, Jeffrey R. Infante, Edward Arrowsmith and Muhammad Wasif Saif and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Cellular Physiology.

In The Last Decade

Mark S. Rubin

13 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark S. Rubin United States 8 336 167 143 107 100 14 492
D. Bafaloukos Greece 13 566 1.7× 176 1.1× 191 1.3× 136 1.3× 185 1.9× 37 777
Dimitrios Krikelis Greece 13 227 0.7× 86 0.5× 167 1.2× 52 0.5× 152 1.5× 21 441
Hyoun Wook Lee South Korea 16 196 0.6× 82 0.5× 281 2.0× 45 0.4× 117 1.2× 57 631
Hongjiang Yan China 14 257 0.8× 60 0.4× 159 1.1× 39 0.4× 110 1.1× 33 543
Naoya Hirakawa Japan 12 215 0.6× 46 0.3× 135 0.9× 47 0.4× 122 1.2× 26 481
N Apostolikas Greece 10 133 0.4× 62 0.4× 140 1.0× 34 0.3× 40 0.4× 22 387
Peter P. Luk Australia 12 282 0.8× 98 0.6× 106 0.7× 109 1.0× 76 0.8× 32 471
Yasunori Ariyoshi Japan 12 227 0.7× 81 0.5× 144 1.0× 87 0.8× 128 1.3× 31 668
Iwao Seshimo Japan 7 411 1.2× 89 0.5× 224 1.6× 20 0.2× 120 1.2× 13 631
Wanja Kildal Norway 14 149 0.4× 60 0.4× 214 1.5× 13 0.1× 188 1.9× 37 625

Countries citing papers authored by Mark S. Rubin

Since Specialization
Citations

This map shows the geographic impact of Mark S. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Rubin more than expected).

Fields of papers citing papers by Mark S. Rubin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Rubin. The network helps show where Mark S. Rubin may publish in the future.

Co-authorship network of co-authors of Mark S. Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Rubin. A scholar is included among the top collaborators of Mark S. Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Rubin. Mark S. Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Hauke, Ralph J., Jeffrey R. Infante, Mark S. Rubin, et al.. (2013). Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma. Melanoma Research. 23(6). 468–473. 15 indexed citations
3.
4.
Gian, Victor G., Mark S. Rubin, Dianna Shipley, et al.. (2012). Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).. Journal of Clinical Oncology. 30(15_suppl). 7587–7587. 2 indexed citations
5.
Spigel, David R., F. Anthony Greco, Mark S. Rubin, et al.. (2012). Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer. 77(2). 359–364. 32 indexed citations
6.
Hauke, Ralph J., Jeffrey R. Infante, Kent C. Shih, et al.. (2012). Everolimus in combination with paclitaxel and carboplatin in patients with advanced melanoma: A phase II trial of the Sarah Cannon Research Institute (SCRI).. Journal of Clinical Oncology. 30(15_suppl). 8556–8556. 2 indexed citations
7.
Hainsworth, John D., Mark S. Rubin, David R. Spigel, et al.. (2012). Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute. Journal of Clinical Oncology. 31(2). 217–223. 235 indexed citations
8.
9.
Hainsworth, John D., Jeffrey R. Infante, David R. Spigel, et al.. (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma. Cancer. 116(17). 4122–4129. 62 indexed citations
10.
Saif, Muhammad Wasif, Nikolai A. Podoltsev, Mark S. Rubin, et al.. (2009). Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer. Cancer Investigation. 28(2). 186–194. 64 indexed citations
11.
Dosoretz, Daniel E., James H. Rubenstein, Michael J. Katin, et al.. (1998). Small-Cell Lung Carcinoma. American Journal of Clinical Oncology. 21(4). 333–337. 3 indexed citations
12.
Bentel, Jacqueline M., David Lebwohl, Kevin J. Cullen, et al.. (1995). Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells. Journal of Cellular Physiology. 165(1). 212–221. 27 indexed citations
13.
Rubin, Mark S.. (1995). A LOOK AT LEGAL ISSUES IN MANAGED CARE, MARKETPLACE CHANGE. The Journal of the American Dental Association. 126(4). 434–436.
14.
Brown‐Elliott, Barbara A., et al.. (1993). LEGAL CONSIDERATIONS IN CASES OF CHILD ABUSE. Primary Care Clinics in Office Practice. 20(2). 407–416. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Bafaloukos Breakdown of academic impact, for papers by Dimitrios Krikelis Breakdown of academic impact, for papers by Hyoun Wook Lee Breakdown of academic impact, for papers by Hongjiang Yan Breakdown of academic impact, for papers by Naoya Hirakawa Breakdown of academic impact, for papers by N Apostolikas Breakdown of academic impact, for papers by Peter P. Luk Breakdown of academic impact, for papers by Yasunori Ariyoshi Breakdown of academic impact, for papers by Iwao Seshimo Breakdown of academic impact, for papers by Wanja Kildal
Rankless by CCL
2026